15% organic revenue growth in FY27
Management expects to sustain 15%+ revenue growth organically for FY27.
CORONAREMEDIES / guidance tracker
Keep management guidance in view.
Corona Remedies · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
25% revenue growth on acquired brands
Acquired brands (Wokadin, Bayer portfolio) are expected to grow at 25% in FY27.
20%+ PAT growth in FY27
Management guided for 20%+ PAT growth in FY27.
Hormone plant operational in Q1/Q2 FY27
The dedicated hormone manufacturing plant is expected to become operational in Q1 or Q2 of FY27.